Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Drug-induced parkinsonism

https://doi.org/10.14412/2074-2711-2021-6-91-97

Full Text:

Abstract

Drug-induced parkinsonism (DIP) is the most common drug-induced movement disorder and is most commonly associated with antipsychotic drugs, monoamine reuptake inhibitors, and calcium channel blockers. DIP manifests as a typical movement disorder, which makes it practically indistinguishable from idiopathic Parkinson's disease (PD) and requires differential diagnosis. DIP symptoms develop fairly quickly (hours to weeks) after the antipsychotic is started or after the dose is increased. Therefore, DIP is predominantly a clinical diagnosis that must be kept in mind when a patient develops typical symptoms during treatment onset or increasing the dose of drugs that most often lead to such an adverse reaction (ADR). DIP evaluation includes using the Naranjo algorithm, which helps assess a causal relationship between drug intake and the development of parkinsonism symptoms. The primary DIP treatment is the reduction of the dose of the inducer drug, or its cancellation, or replacement with another drug. In patients with schizophrenia and antipsychotic-induced DIP, dose reduction, replacement with another medication, or prescription of a drug with anticholinergic activity may be possible. The awareness of the doctor and the patient about the possibility of developing this ADR is crucial in the prevention of DIP. Therefore, choosing a drug with the lowest risk of developing DIP is necessary for pharmacotherapy.

About the Authors

T. M. Ostroumova
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 11, Rossolimo St., Build. 1, Moscow 119021, Russia 



O. D. Ostroumova
Department of therapy and polymorbid pathology, Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russia 

 11, Rossolimo St., Build. 2, Moscow 119021, Russia 



A. S. Soloveva
N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

 11, Rossolimo St., Build. 2, Moscow 119021, Russia 



References

1. Tisdale JE, Miller DA, eds. Drug-induced diseases: prevention, detection, and management 3rd edition. Bethesda, Md: American Society of Health-System Pharmacists; 2018.

2. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012 Mar;8(1):15-21. doi: 10.3988/jcn.2012.8.1.15

3. Levin OS, Shindryaeva NN, Anikina MA Drug-induced parkinsonism. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(8):76-81 (In Russ.).

4. Nodel MR. Drug-induced parkinsonism:opportunities to minimize risk. Nervnye bolezni.2015;(3):18-22 (In Russ.).

5. Kumsa A, Girma S, Alemu B, Agenagnew L. Psychotropic medicationsinduced tardive dyskinesia and associated factors among patients with mental illness in Ethiopia. Clin Pharmacol. 2020 Dec 1;12:179-87. doi: 10.2147/CPAA.S285585. eCollection 2020.

6. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27.

7. Chyou TY, Nishtala R, Nishtala PS. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults – a propensity score matched cohort study. Pharmacoepidemiol Drug Saf. 2020 Jun;29(6):692-700. doi: 10.1002/pds.5007. Epub 2020 Apr 16.

8. Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011 Oct;26(12):2226-31. doi: 10.1002/mds.23828. Epub 2011 Jun 14.

9. Tsai SC, Sheu SY, Chien LN, et al. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study. Br J Clin Pharmacol. 2018 Sep;84(9):2000-9. doi: 10.1111/bcp.13630. Epub 2018 Jun 19.

10. Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019 Jun 20;10:2042098619854007. doi: 10.1177/2042098619854007. eCollection 2019.

11. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011 Apr;45(4):525-31. doi: 10.1345/aph.1P312. Epub 2011 Apr 12.

12. Sahin T, Yilmaz R, Akbostanci MC. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders. Parkinsonism Relat Disord. 2020 May;74:36-7. doi: 10.1016/j.parkreldis.2020.04.007. Epub 2020 Apr 14.

13. Guay DR. Tetrabenazine, a monoaminedepleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73. doi: 10.1016/j.amjopharm.2010.08.006

14. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15;22(2):193-7. doi: 10.1002/mds.21222

15. Teive HA, Troiano AR, Germiniani FM, Werneck LC. Flunarizine and cinnarizineinduced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004 Jun;10(4):243-5. doi: 10.1016/j.parkreldis.2003.12.004

16. Lin HL, Lin HC, Tseng YF, et al. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol. 2017 Mar;73(3):365-71. doi: 10.1007/s00228-016-2181-3

17. Miguel R, Correia AS, Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Parkinsons Dis. 2014;4(4):645-9. doi: 10.3233/JPD-140414

18. Kim S, Cheon SM, Suh HS. Association between drug exposure and occurrence of parkinsonism in Korea: a population-based case-control study. Ann Pharmacother. 2019 Nov;53(11):1102-10. doi: 10.1177/1060028019859543. Epub 2019 Jun 19.

19. Jhang KM, Huang JY, Nfor ON, et al. Flunarizine related movement disorders: a nationwide population-based study. Sci Rep. 2019 Feb 8;9(1):1705. doi: 10.1038/s41598-018-37901-z

20. Liang CY, Yeh YC, Lee CJ, Chen YY. Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study. J Clin Neurosci. 2018 Apr;50:281-6. doi: 10.1016/j.jocn.2018.01.017. Epub 2018 Feb 1.

21. Padrell MD, Navarro M, Faura CC, Horga JF. Verapamil-induced parkinsonism. Am J Med. 1995 Oct;99(4):436. doi: 10.1016/s0002-9343(99)80195-8

22. Revet A, Montastruc F, Roussin A, et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020 Jun 16;20(1):308. doi: 10.1186/s12888-020-02711-z

23. Miletic V, Relja M. Citalopram-induced parkinsonian syndrome: case report. Clin Neuropharmacol. Mar-Apr 2011;34(2):92-3. doi: 10.1097/WNF.0b013e318210ea3e

24. Ak S, Anil Yagcioglu AE. Escitalopraminduced Parkinsonism. Gen Hosp Psychiatry. Jan-Feb 2014;36(1):126.e1-2. doi: 10.1016/j.genhosppsych.2013.09.010. Epub 2013 Oct 5.

25. Kuloglu M, Caykoylu A, Ekinci O, et al. Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. J Psychopharmacol. 2010 Apr;24(4):623-4. doi: 10.1177/0269881108099962. Epub 2008 Dec 12.

26. Christodoulou C, Papadopoulou A, Rizos E, et al. Extrapyramidal side effects and suicidal ideation under fluoxetine treatment: a case report. Ann Gen Psychiatry. 2010 Jan 18;9:5. doi: 10.1186/1744-859X-9-5

27. Gray JA. Parkinsonism and rabbit syndrome after discontinuation of low-dose ziprasidone and concomitant initiation of sertraline. J Clin Psychopharmacol. 2012 Feb;32(1):142-3. doi: 10.1097/JCP.0b013e31823f912a

28. Pina Latorre MA, Modrego PJ, Rodilla F, et al. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther. 2001 Apr;26(2):111-2. doi: 10.1046/j.1365-2710.2001.00307.x

29. Bayrak A, Cetin B, Meteris H, Kesebir S. Parkinsonism secondary to duloxetine use: a case report. North Clin Istanb. 2015 Dec 25;2(3):243-6. doi: 10.14744/nci.2015.63634. eCollection 2015.

30. Hong JY, Sunwoo MK, Oh JS, et al. Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging. PLoS One. 2016 Jun 13;11(6):e0157410. doi: 10.1371/journal.pone.0157410. eCollection 2016.

31. Sarwar AI. Trazodone and parkinsonism: the link strengthens. Clin Neuropharmacol. May/Jun 2018;41(3):106-8. doi: 10.1097/WNF.0000000000000278

32. Brugger F, Bhatia KP, Besag FM. Valproateassociated parkinsonism: a critical review of the literature. CNS Drugs. 2016 Jun;30(6):527-40. doi: 10.1007/s40263-016-0341-8

33. Yomtoob J, Koloms K, Bega D. DAT-SPECT imaging in cases of drug-induced parkinsonism in a specialty movement disorders practice. Parkinsonism Relat Disord. 2018 Aug;53:37-41. doi: 10.1016/j.parkreldis.2018.04.037. Epub 2018 May 5.

34. Ristic AJ, Vojvodic N, Jankovic S, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006 Dec;47(12):2183-5. doi: 10.1111/j.1528-1167.2006.00711.x

35. Muralidharan A, Rahman J, Banerjee D, et al. Parkinsonism: a rare adverse effect of valproic acid. Cureus. 2020 Jun 23;12(6):e8782. doi: 10.7759/cureus.8782

36. Pacheco-Paez T, Montastruc F, Rousseau V, et al. Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study. Mov Disord. 2020 Jan;35(1):176-80. doi: 10.1002/mds.27876. Epub 2019 Oct 21.

37. Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. Clin Neuropharmacol. May/Jun 2020;43(3):66-80. doi: 10.1097/WNF.0000000000000387

38. Marras C, Herrmann N, Fischer HD, et al. Lithium use in older adults is associated with increased prescribing of parkinson medications. Am J Geriatr Psychiatry. 2016 Apr;24(4):301-9. doi: 10.1016/j.jagp.2015.11.004. Epub 2015 Dec 10.

39. Gmitterova K, Minar M, Zigrai M, et al. Tacrolimus-induced parkinsonism in a patient after liver transplantation – case report. BMC Neurol. 2018 Apr 20;18(1):44. doi: 10.1186/s12883-018-1052-1

40. Ling H, Bhidayasiri R. Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation. Mov Disord. 2009 Sep 15;24(12):1848-9. doi: 10.1002/mds.22530

41. Montastruc JL, Durrieu G. Amiodarone and Parkinsonism: a pharmacovigilance study. Fundam Clin Pharmacol. 2021 Aug;35(4):781-4. doi: 10.1111/fcp.12618. Epub 2020 Nov 9.

42. Dotti MT, Federico A. Amiodaroneinduced parkinsonism: a case report and pathogenetic discussion. Mov Disorders. 1995 Mar;10(2):233-4. doi: 10.1002/mds.870100223

43. Malaterre HR, Renou C, Kallee K, Gauthier A. Akinesia and amiodarone therapy. Int J Cardiol. 1997 Mar;59(1):107-8. doi: 10.1016/s0167-5273(96)02891-4

44. Ishida S, Sugino M, Hosokawa T, et al. Amiodarone-induced liver cirrhosis and parkinsonism: a case report. Clin Neuropathol. MarApr 2010;29(2):84-8. doi: 10.5414/npp29084

45. Sandyk R. Parkinsonism induced by captopril. Clin Neuropharmacol. 1985;8(2):197-8. doi: 10.1097/00002826-198506000-00013

46. Fisher JF, Dewald J. Parkinsonism associated with intraventricular amphotericin B. J Antimicrob Chemother. 1983 Jul;12(1):97-9. doi: 10.1093/jac/12.1.97

47. Miguelez C, Morera-Herreras T, Torrecilla M, et al. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuits. 2014 Mar 17;8:21. doi: 10.3389/fncir.2014.00021. eCollection 2014.

48. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008 Aug;11(5):625-39. doi: 10.1017/S1461145707008383. Epub 2008 Jan 21.

49. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Treatment of antipsychoticinduced parkinsonism in schizophrenic patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):4-11. doi: 10.14412/2074-2711-20214-4-11 (In Russ.).

50. Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther. 2018 Dec;7(2):233-248. doi: 10.1007/s40120-018-0105-0. Epub 2018 Jul 19.

51. Wisidagama S, Selladurai A, Wu P, et al. Recognition and management of antipsychoticinduced parkinsonism in older adults: a narrative review. Medicines (Basel). 2021 May 26;8(6):24. doi: 10.3390/medicines8060024

52. De Germay S, Montastruc F, Carvajal A, et al. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 Jan;70:55-9. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17.

53. Pieters LE, Bakker PR, van Harten PN. Asymmetric drug-induced parkinsonism and psychopathology: a prospective naturalistic study in long-stay psychiatric patients. Front Psychiatry. 2018 Feb 5;9:18. doi: 10.3389/fpsyt.2018.00018. eCollection 2018.

54. Savica R, Grossardt BR, Bower JH, et al. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Mov Disord. 2017 Feb;32(2):227-34. doi: 10.1002/mds.26839. Epub 2016 Oct 25.

55. Munhoz RP, Bertucci Filho D, Teive HA. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype. Neurol Sci. 2017 Feb;38(2):319-24. doi: 10.1007/s10072-016-2771-y. Epub 2016 Nov 16.

56. Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012 Oct 9;79(15):1615-21. doi: 10.1212/WNL.0b013e31826e25ce. Epub 2012 Sep 26.

57. Jeong S, Cho H, Kim YJ, et al. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease. PLoS One. 2021 Mar 1;16(3):e0247354. doi: 10.1371/journal.pone.0247354. eCollection 2021.

58. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: A double-hit hypothesis? Mov Disord. 2015 May;30(6):780-5. doi: 10.1002/mds.26209. Epub 2015 Mar 18.

59. The American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021. doi: 10.1176/appi.books.9780890424841

60. Morley JF, Duda JE. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease. J Parkinsons Dis. 2014;4(2):169-73. doi: 10.3233/JPD-130299

61. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154

62. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Farmakonadzor. Farmateka. 2020;(6):113-26. doi: 10.18565/pharmateca.2020.6.113-126 (In Russ.).

63. Sapronova MR, Dmitrenko DV, Schnaider NA, Molgachev AA. Diagnosis of Parkinson’s Disease. Part 1. The Potential of Functional Neuroimaging. Doctor.Ru. 2020;19(9):6-12. doi: 10.31550/1727-2378-2020-19-9-6-12 (In Russ.).

64. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1885-912. doi: 10.1007/s00259-020-04817-8. Epub 2020 May 9.

65. Bega D, Kuo PH, Chalkidou A, et al. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 2021 May 24;7(1):43. doi: 10.1038/s41531-021-00185-8

66. Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):372-4. doi: 10.1136/jnnp.2005.073999. Epub 2005 Aug 15.

67. Tachibana K, Matsuura K, Shindo A, et al. Symptomatic characteristics of parkinson's disease induced by neuroleptic drugs, based on a functional neuroimaging diagnosis. Intern Med. 2020;59(4):485-90. doi: 10.2169/internalmedicine.2553-18. Epub 2020 Feb 15.

68. Caproni S, Colosimo C. Diagnosis and differential diagnosis of parkinson disease. Clin Geriatr Med. 2020 Feb;36(1):13-24. doi: 10.1016/j.cger.2019.09.014. Epub 2019 Sep 17.


For citation:


Ostroumova T.M., Ostroumova O.D., Soloveva A.S. Drug-induced parkinsonism. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):91-97. https://doi.org/10.14412/2074-2711-2021-6-91-97

Views: 75


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)